Cyclic AMP and platelet prostaglandin synthesis

doi:10.1016/0090-6980(77)90155-1

Prostaglandins

Volume 14, Issue 1, July 1977, Pages 39-50

Prostaglandins

https://doi.org/10.1016/0090-6980(77)90155-1 Get rights and content

Abstract

The present study has investigated the influence of agents which elevate intracellular levels of endogenous platelet adenosine 3′5′-cyclic monophosphate (cyclic AMP), and the effect of the exogenous cyclic AMP analog, dibutyryl cyclic AMP, on the conversion of ¹⁴C-arachidonic acid by washed platelets. Prostaglandin E₁ (PGE₁), PGE₁ with theophylline, or dibutyryl cyclic AMP incubated with washed platelets prevented arachidonic acid induced platelet aggregation, but had no effect on the conversion of arachidonic acid to 12L-hydroxy-5,8,10, 14-eicosatetraenoic acid (HETE), 12L-hydroxy-5,8,10 heptadecatrienoic acid (HHT), or thromboxane B₂. Ultrastructural studies of the platelet response revealed that agents acting directly or indirectly to increase the level of cyclic AMP inhibited the action of arachidonic acid on washed platelets and prevented internal platelet contraction as well as aggregation. The influence of PGE₁ with theophylline, and dibutyryl cyclic AMP on the thrombin induced release of ¹⁴C-arachidonic acid from platelet membrane phospholipids was also investigated. These agents were found to be potent inhibitors of the thrombin stimulated release of arachidonic acid from platelet phospholipids, due most likely to an inhibition of platelet phospholipase A activity. The results show that dibutyryl cyclic AMP and agents which elevate intracellular cyclic AMP levels act to inhibit platelet activation at two steps 1) internal contraction and 2) release of arachidonic acid from platelet phospholipids.

References (18)

N.R. Marquis et al.
Platelet Aggregation
C. Malmsten et al.
Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG₂) in human platelets
Biochem. Biophys. Res. Commun.
(1976)
T.K. Bills et al.
Metabolism of [¹⁴C] arachidonic acid by human platelets
Biochimica et Biophysica Acta
(1976)
G.R. Bartlett
Phosphorous assay in column chromatography
J. Biol. Chem.
(1959)
A. Derksen et al.
Patterns of fatty acid release from endogenous substrates by human platelets, homogenates and membranes
J. Biol. Chem.
(1975)
E.W. Salzman et al.
Cyclic 3′5′-adenosine monophosphate in human blood platelets
D.C.B. Mills et al.
The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′5′-cyclic monophosphate in platelets
Biochem. J.
(1971)
R.J. Haslam
Roles of cyclic nucleotides in platelet function
H.J. Day et al.
Concepts of the blood platelet release reaction
Ser. Haemat.
(1971)

There are more references available in the full text version of this article.

Cited by (69)

Inhibition of platelet function by the endothelium
2019, Platelets
During hemostasis, pro- and anti-thrombotic processes are balanced to maintain vascular patency. These processes, described as thromboregulation, require the utilization of several major endothelial pathways to regulate platelet activation, including: (1) nitric oxide (NO); (2) eicosanoid prostacyclin (PGI₂); and (3) ectonucleotidase CD39. Moreover, platelets are diverse in size and have differential distribution of receptors, providing an additional level of regulation. This chapter discusses these thromboregulatory mechanisms in detail, highlighting the signaling pathways involved in endothelial-mediated inhibition of platelet function, and the role of these pathways in disease development. Animal models and clinical investigations related to these mechanisms are discussed, as are emerging concepts in the regulation of platelet activation as a function of platelet heterogeneity.
Inhibition of Platelet Function by the Endothelium
2013, Platelets
Inhibition of Platelet Function by the Endothelium
2012, Platelets, Third Edition
Inhibition of platelet function by the endothelium
2007, Platelets
Inhibition of platelet function by the endothelium
2006, Platelets, Second Edition
Oxidized low-density lipoprotein (LDL) enhances thromboxane A<inf>2</inf> synthesis by platelets, but lysolecithin as a product of LDL oxidation has an inhibitory effect
2000, Prostaglandins and Other Lipid Mediators
Oxidation of low-density lipoprotein (LDL) by copper sulfate led to a significant increase in lysophosphatidylcholine (lyso PC) at the expense of phosphatidylcholine. Incubation of different concentrations of oxidized LDL (oxLDL) (32–650 μg protein/ml) with platelets for 1 h at 37°C increased lyso PC content. The increase was dependent on oxLDL concentration. Incubation of platelets with various concentrations of lyso PC in solution for 5 or 15 min showed that lyso PC percentage was increased in the platelet membrane and the increase was dose dependent. Platelets incubated with various concentrations of lyso PC (2–100 μM) for 5 or 15 min and then triggered with thrombin also showed a significant decrease of thromboxane A₂ (TXA₂) release as lyso PC concentration reached 10 μM or 6 μM, respectively. The decrease of TXA₂ release was more significant as lyso PC concentration was increased. The present study showed that this inhibition of TXA₂ release by lyso PC was due to 1) inhibition of phospholipase A₂ and the decrease of free arachidonic acid liberation from platelet phospholipid and 2) inhibition of cyclooxygenase. These inhibitory effects of lyso PC were discussed in relation to its effect on membrane fluidity. Lyso PC at concentrations of 30, 50, and 100 μM caused a sudden drop in TXA₂ release and a sudden increase of lactic dehydrogenase loss from the platelets due to their lysis and inhibition of cyclooxygenase enzyme. The present study shows that oxLDL contains high levels of lyso PC that are transferable to the platelets and can weaken their responsiveness to thrombin and decrease TXA₂ release. In our previous study, we found that oxLDL also contained high levels of oxysterols and thiobarbituric acid reactive substances (TBARS), which enhanced platelet reactivity to thrombin and increased TXA₂ release. We conclude that the net effect of oxLDL on platelets will depend on its degree of oxidation and the ratio between oxysterols plus TBARS/lyso PC. Variations in this ratio may explain some of the contradictions cited in the literature concerning the effect of oxLDL on platelet activation.

View all citing articles on Scopus

View full text

Cyclic AMP and platelet prostaglandin synthesis

Abstract

Biochem. Biophys. Res. Commun.

Biochimica et Biophysica Acta

J. Biol. Chem.

J. Biol. Chem.

Cyclic 3′5′-adenosine monophosphate in human blood platelets

The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′5′-cyclic monophosphate in platelets

Biochem. J.

Roles of cyclic nucleotides in platelet function

Concepts of the blood platelet release reaction

Ser. Haemat.